Related content

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 118-122

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III ‘Stop and Go' Study Results - A Turkish Oncology Group Trial

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 328-335

Karger

Access to resources Recommend Favorite

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 12, 2014-12 ,pp. : 3255-3264

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study

By  

EPILEPSIA, Vol. 59, Iss. 2, 2018-02 ,pp. : 479-491

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase III clinical trial with a 28‐week extension

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 599-602

John Wiley & Sons Inc

Access to resources Recommend Favorite